You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Further response to ‘Decision to reject screening for familial hypercholesterolaemia is flawed’ by Wald and Martin
  1. David S Wald1,
  2. Andrew C Martin2
  1. 1 Population Health Research Institute, St George's University of London, London, UK
  2. 2 Department of General Paediatrics, Perth Children's Hospital, Nedlands, Western Australia, Australia
  1. Correspondence to Professor David S Wald, Population Health Research Institute, St George's University of London, London SW17 0RE, UK; dwald{at}sgul.ac.uk

https://doi.org/10.1136/archdischild-2021-322934

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We were surprised and disappointed by the National Screening Committee (NSC)’s response to our paper.1 2 The NSC believes that a child with familial hypercholesterolaemia (FH) may not benefit from being identified at age 1 year, but does benefit if identified at age 10 when statins are more likely to be offered. The advantages of screening at age 1 year have been given before but do not seem to be recognised by the NSC. We list them here:

    1. It is the most accurate time in life to identify individuals with FH, because cholesterol measurement from 1 to 9 years offers the best discrimination between people …

    View Full Text

    Footnotes

    • Contributors DSW and ACM contributed equally to the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Linked Articles